Floatz logo

Metformin

Bronchioloalveolar Carcinoma

NRG OncologySmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Bronchioloalveolar Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
NRG Oncology
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 2B
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
PEGFILGRASTIM
National Cancer Institute (NCI)
Phase 2CCC
FILGRASTIM
National Cancer Institute (NCI)
Phase 2CCC

View all 10 →

Same molecule, other indications

Metformin is also rated in:

Metabolism and Nutrition DisorderDormant
A
Indicative ·
82 / 100
View asset →
prediabetes syndromeDormant
A
Indicative ·
81 / 100
View asset →
gestational diabetesDormant
A
Indicative ·
81 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →